SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The community is rallying behind the multichain meme project crow with knife, highlighting its deflationary burn mechanism and organic growth as primary drivers of their bullish sentiment. Discussions are dominated by high-energy engagement and a strong conviction that the token serves as a unique asset within the current meme coin landscape.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its status as a long-standing parody of Bitcoin, with users debating whether its satirical roots give it staying power as a legitimate asset. Supporters are actively pointing to its unique lore, growing holder count, and high-profile endorsements as catalysts, while others remain skeptical, fueling a polarized discussion about its long-term potential in the meme coin space.

Maulcoin

Maulcoin is trending as its community aggressively rallies behind the project's organic growth and 'join the dark side' branding, with members actively pushing for social engagement and new listings to drive the next wave of price appreciation. Investors are heavily focused on holding through dips and hitting specific market cap milestones that trigger community-wide airdrops, highlighting a strong collective sentiment centered on long-term accumulation rather than short-term gains.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and negative sentiment as investors express frustration over prolonged stagnant price action and its consistent underperformance compared to other assets. The community is actively debating the project's long-term utility versus its speculative nature, while many are focused on the impact of upcoming legislative developments and potential accumulation opportunities during this period of high volatility.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as the market reacts to shifting geopolitical tensions between the U.S. and Iran, with traders intensely debating whether current diplomatic stalemate signals a deeper correction or a massive short squeeze. Community sentiment is deeply polarized, with bulls pointing to robust institutional ETF inflows and long-term accumulation as a floor, while bears are focused on potential macroeconomic fallout from prolonged conflict and the risk of a breakdown in technical support levels.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social engagement as the community reacts to a recent Google research paper that cites its protocol as a benchmark for quantum-resistant security, while investors remain split between long-term optimism regarding its enterprise utility and frustration over extended price volatility.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector, tracked by SMH, is experiencing intense volatility as investors debate whether current AI capital expenditure is a sustainable growth engine or a crowded, overextended bubble. Community discussion is sharply divided between those monitoring critical technical support levels and those convinced that cooling AI demand and macroeconomic headwinds will inevitably trigger a broad-based market correction.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is currently at the center of market attention as investors monitor its exposure to private credit stress and potential shifts in bank capital requirements. The community is actively debating its valuation relative to growth prospects, with many traders closely watching technical levels ahead of the upcoming earnings cycle and broader sentiment on the banking sector.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care (FMS) is trending as the community debates the competitive landscape for infection prevention in dialysis, specifically regarding the adoption and impact of antimicrobial catheter lock solutions like Defencath. Investors are actively tracking potential partnerships and the strategic implications of these technologies on facility-level infection metrics as operators strive to improve patient safety outcomes.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is capturing market attention as its integration with Telegram reaches a massive user base, with traders highlighting recent sub-second network upgrades and high APY staking opportunities. Community discussion is currently centered on increased institutional adoption, including new ETP listings and strategic whale accumulation despite recent price volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jeff Knight Sells 85,163 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the company's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total transaction of $3,415,036.30. Following the completion of the sale...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Jeff Knight Sells 85,163 Shares

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Jeff Knight sold 85,163 shares of the business's stock in a transaction that occurred on Wednesday, April 8th. The stock was...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 3rd...

Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Aberdeen Group plc lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 98.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered Crinetics Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Key PointsA director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 4.3% - Time to Sell...

JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

JPMorgan Chase & Co. lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 279.2% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,258,722 shares of the company's stock after acquiring an additional 926,765 share...

Richard Scott Struthers Sells 21,981 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 21,981 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Current Price	$39.44
Prev Close	$39.63
Open	$39.63
Dividend Yield	0.00%
50-Day Moving Average	$40.79
Beta	1.19
Avg. Volume	1.24M
PE Ratio	-7.98

52-Week High	$57.99
52-Week Low	$25.83
Market Capitalization	$4.13B
EPS (Annual)	-$4.95
Price to Book	3.80
Revenue Per Employee	$12,956.23

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc